EuroTEST
Working together for integrated testing and earlier care

HepHIV 2026
by EuroTEST
2-3 NOVEMBER · DUBLIN

Gaps in HBV, HCV and HPV prevention, testing and care in European prisons, findings from 21 facilities in seven countries

Ricardo Fuertes et al.

University of Pisa and PACE Consortium

www.prisonhealth.eu

Co-funded by the European Union

PACE
PATH TO EQUITY: EXPANDING ACCESS TO CANCER-PREVENTING VACCINATION FOR ADULTS AND JUVENILES IN EUROPEAN CARCERAL SETTINGS

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.

PACE – Path to Equity

Why PACE?

People in prisons face a high burden of infectious diseases and persistent gaps in prevention and care

Europe's Beating Cancer Plan (2021) and the Council of the EU Recommendation on vaccine-preventable cancers (2024)

Objective

Adapt and implement evidence-based interventions to reduce cancers related to viral hepatitis and HPV in prisons and juvenile detention settings

EU4Health / November 2025 – October 2028

Cyprus · France · Greece · Italy · Moldova · Portugal · Romania



Gap Analysis to Pathfinder implementation

WP4 knowledge sharing and sustainability

Collection of best practices, International Network of professionals



WP5.1 Identify gaps

National Survey, **Facility-level survey**

October 26



WP5.2 Select Priorities and Interventions

Agree a methodology for the pathfinders

Nov 2026

WP6 Implement and Evaluate Interventions

Start Pathfinders in at least one prison per country

Aug 2027

Pathfinders

Interventions adapted to local needs, tested and refined through implementation, with the potential to be scaled up



WP7 Capacity building on monitoring

Training on data collection and analysis. Creation of a Sentinel Network of Prisons

Facility-Level GAP Analysis - Methodology

1. **Selection of areas and indicators:** facility characteristics, vaccination, testing, treatment and harm reduction

2. **Survey development:** facility questionnaire and self-assessment questions

3. **Pilot and review:** consultation with project partners and prison health experts

4. **Data collection:** REDCap, May–July 2026

5. **Data validation:** September–October 2026 **ongoing**

Key reference documents:





EUDA
EUROPEAN UNION DRUGS AGENCY

European Facility Survey Questionnaire - Prisons

INHSU PRISONS

Global Guidelines for Viral Hepatitis Service Delivery in Prisons

INTERNATIONAL NETWORK ON HEALTH AND HEPATITIS IN SUBSTANCE USERS – PRISONS (INHSU PRISONS)

Facilities Participating in the Gap Analysis

21
Facilities

13,347
People detained

62%
Above capacity

Facility characteristics

64–1,766 people per facility

Sentenced, remand and open prisons

Population

10 facilities accommodating minors

9 facilities accommodating women

4 facilities accommodating transgender persons

56% of facilities with over 20% non-nationals



Beyond Availability: Assessing Implementation

Reported availability

Facilities reporting the service as available



Implementation self-assessment

Tier 0	Not implemented / service unavailable
Tier 1	Limited or occasional implementation
Tier 2	Partial implementation
Tier 3	Comprehensive, structured implementation

Availability does not tell us who receives care, how/when services are delivered, or whether care continues after transfer or release

HCV – Implementation Self Assessment

HCV Testing

Availability 95%	Testing timing 76%
Exists in 20/21 facilities	Systematically offered at entry and repeated during detention according to risk or protocol (16/21, T3)

HCV Treatment

Availability 95%	Treatment access 71%	Continuity of care 38%
Exists in 20/21 facilities	Treatment offered to all diagnosed (15/21, T3)	Active handover at release or transfer, with appointment scheduling and transfer of clinical information (8/21, T3)

Country	Facility	Testing timing	Treatment access	Care continuity
CY	CY-68			
FR	FR-77			
	FR-78			
	FR-79			
	FR-105			
GR	GR-82			
	GR-83			
	GR-101			
IT	IT-53			
	IT-55			
	IT-58			
	IT-90			
PT	PT-74			
	PT-76			
	PT-99			
MD	MD-50			
	MD-73			
	MD-80			
RO	RO-70			
	RO-72			
	RO-93			

Tier 0 Tier 1 Tier 2 Tier 3

HBV – Implementation Self Assessment

HBV Vaccination

Availability 86%	Vaccination completion 19%
Exists in 18/21 facilities	Systems to ensure completed vaccination courses (4/21, T3)

HBV Testing

Availability 95%	Testing timing 67%
Exists in 20/21 facilities	Testing systematically at entry and repeating during detention according to risk or protocol (14/21, T3)

HBV Treatment

Availability 86%	Treatment access 52%	Continuity of care 24%
Exists in 18/21 facilities	Treatment offered to all medically eligible (11/21, T3)	Active handover at release/transfer, with appointment scheduling and transfer of clinical information (5/21, T3)



Self Assessment- HPV

HPV Vaccination

Availability 71%

Exists in 15/21 facilities

Vaccination target 38%

Offered to all medically eligible groups, according to national guidelines

(18/21, T3)

Cervical Cancer Screening

Availability 89%

Exists in 8/9 facilities

Screening Target 11%

Eligible individuals systematically identified for screening, in line with national guidelines

(1/9, T3)

Country	Facility	HPV vaccination target	Cervical screening target
CY	CY-68		
FR	FR-77		
	FR-78		
	FR-79		
	FR-105		
GR	GR-82		
	GR-83		
	GR-101		
IT	IT-53		
	IT-55		
	IT-58		
	IT-90		
PT	PT-74		
	PT-76		
	PT-99		
MD	MD-50		
	MD-73		
	MD-80		
RO	RO-70		
	RO-72		
	RO-93		

Tier 0 Tier 1 Tier 2 Tier 3

Self Assessment – Harm Reduction and Prevention

OAT

Availability 71%

Exists in 15/21 facilities

Accessible 62%

Offered for continuity and initiation (13/21, T2-3)

Condoms

Availability 57%

Exists in 12/21 facilities

Accessible 14%

Discretely and widely available (3/21, T3)

NSP

Availability 29%

Exists in 6/21 facilities (T1-3)

Naloxone at release

Availability 24%

Exists in 5/21 facilities (T1-3)

Country	Facility	OAT	NSP	Condoms and lubricants	HIV PrEP	Naloxone in prison	Naloxone at release
CY	CY-68	Tier 2	Tier 0	Tier 0	Tier 0	Tier 0	Tier 0
FR	FR-77	Tier 2	Tier 0	Tier 1	Tier 2	Tier 1	Tier 2
	FR-78	Tier 3	Tier 3	Tier 2	Tier 3	Tier 2	Tier 3
	FR-79	Tier 3	Tier 3	Tier 2	Tier 3	Tier 2	Tier 3
	FR-105	Tier 3	Tier 0	Tier 2	Tier 0	Tier 2	Tier 3
GR	GR-82	Tier 0	Tier 0	Tier 0	Tier 0	Tier 0	Tier 0
	GR-83	Tier 0	Tier 0	Tier 0	Tier 0	Tier 0	Tier 0
	GR-101	Tier 1	Tier 0	Tier 0	Tier 0	Tier 2	Tier 0
IT	IT-53	Tier 3	Tier 0	Tier 0	Tier 1	Tier 0	Tier 0
	IT-55	Tier 3	Tier 0	Tier 0	Tier 0	Tier 2	Tier 0
	IT-58	Tier 0	Tier 0	Tier 0	Tier 0	Tier 1	Tier 0
	IT-90	Tier 2	Tier 0	Tier 0	Tier 0	Tier 2	Tier 0
PT	PT-74	Tier 3	Tier 0	Tier 2	Tier 2	Tier 2	Tier 2
	PT-76	Tier 2	Tier 0	Tier 2	Tier 0	Tier 1	Tier 0
	PT-99	Tier 0	Tier 0	Tier 2	Tier 0	Tier 0	Tier 0
MD	MD-50	Tier 3	Tier 3	Tier 3	Tier 2	Tier 2	Tier 0
	MD-73	Tier 3	Tier 3	Tier 3	Tier 2	Tier 2	Tier 0
	MD-80	Tier 3	Tier 3	Tier 3	Tier 2	Tier 2	Tier 0
RO	RO-70	Tier 0	Tier 0	Tier 0	Tier 0	Tier 0	Tier 0
	RO-72	Tier 1	Tier 0	Tier 2	Tier 2	Tier 0	Tier 0
	RO-93	Tier 0	Tier 2	Tier 2	Tier 0	Tier 0	Tier 0

Tier 0 Tier 1 Tier 2 Tier 3

Education, Training, Awareness – Self Assessment

Structured Interventions* for Key Populations and Stigma (T3)

* Education, training, awareness, specific minorities interventions

People who use drugs 57% (12/21)

Women 33% (3/9)

LGBTQI+ 5% (1/21)

Migrants/Ethnic Minorities 5% (1/21)

Addressing Stigma 24% (5/21)



Conclusions and Next Steps

- Considerable variation in service implementation across countries and across facilities
- Despite reported service availability, important gaps remain in access, timing and continuity of care
- Harm reduction services and interventions for vulnerable populations are very limited

- Facility self-assessments, complemented by quantitative indicators, will guide the selection and implementation of Pathfinders interventions

Co-authors

Lara Tavoschi, Virginia Casigliani, Erica De Vita, Filipa Alves da Costa, Fadi Meroueh, Antonella Grisolia, Roberto Ranieri, Josefina Mavrou, Laura Baglietto, Angela Bardelli, Maria Laura Russo, Rita Guedes, Aurelie Mieuset, Penelope Robin, Dalma Archontoula, Valentin Zaharia, Vlad Busmachiu, Irina Barbîroș, Evi Kyprianou, Iakovos Stylianou

Acknowledgements

Nicola Cocco, Chirila Vlad Alexandru, Deborah Iwanikow, Emmanuelle David, Fatima Quaresma, Iutis Marin, Madalina Albu, Maria Helena Cardoso, Maria Shiali, Nikolaos Drougos, Panagiotis Yourazolos, Raluca Smarandescu, Raul Guardo Salinas, Rute Mendes, Tatiana Coretchi, Thomas Chachamis, Victor Iacovet



Co-funded by the European Union

PACE
PATH TO EQUITY: EXPANDING ACCESS TO CANCER-PREVENTING VACCINATION FOR ADULTS AND JUVENILES IN EUROPEAN CARCERAL SETTINGS

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA Neither the European Union nor the granting authority can be held responsible for them.